MAPT and Alzheimer disease: Several in vitro and in vivo studies have reported positive effects of luteolin on reducing ROS production (Dragicevic et al., 2011), restoring ATP levels (Dragicevic et al., 2011), increasing synaptic marker expression (Xu et al., 2013), reducing pathological hallmarks of AD and decreasing Aβ production and tau phosphorylation (Sawmiller et al., 2014), and restoring cognitive functions (Wang et al., 2016).